Six weeks of diving in water cold enough to kill. Depths of 130 feet. Half-hour bottom times.
That was the price of collecting one tiny sea squirt off Antarctica. Now that creature’s toxin has killed melanoma in mice.
The mice survived. That is the first gate a potential drug must pass. The University of South Florida team that brought back the specimens did not set out to cure skin cancer.
They went looking for chemical defenses. Antarctic ascidians — rubbery invertebrates that look like blobs — sit on the seafloor and cannot flee.
So they manufacture poisons. Predators take one bite and learn. Bill Baker, the USF chemist leading the research, calls it repurposing.
Nature built those toxins to kill cells. Cancer cells are, after all, just cells that refuse to die. The trick is making the poison pick the right target.
In mice, it did. “The good news is it didn’t kill the mice,” Baker said.
“It did kill their cancer, so we know it has the physiological properties to act like a drug.” That distinction matters. Many compounds kill cancer in a dish. Fewer kill it in a living animal without killing the animal.
The gap between those two outcomes is where most would-be drugs die. The expedition was funded by the National Science Foundation.
Ben Meister, the diving safety officer on the trip, described the conditions as brutal. Divers worked in near-freezing water. They had minutes, not hours, to find specimens on the bottom.
The Antarctic summer offers little warmth and less margin for error. What they brought back was grams of material. That is enough for the next round of mouse studies.
It is not enough for human trials. Baker spelled out the math: “We need grams of material to do a bigger study in mice, perhaps go into other animal models, and if we can prove the safety, we can actually start some human trials.” The path from grams to a prescription bottle is measured in years and millions of dollars.
The compound must be synthesized or harvested in quantity. It must pass toxicity screens. It must work in larger animals.
Then, if all those gates open, the FDA allows a Phase I trial in humans — a safety test, not a cure test. Most compounds never get that far.
Melanoma is the deadliest skin cancer. It kills roughly 8,000 Americans each year. Treatments have improved — checkpoint inhibitors, targeted therapies — but they fail in many patients.
Resistance is common. The need for new chemical tools is real. The Antarctic angle is not a gimmick.
Cold-water organisms live under extreme pressure and near-zero temperatures. Their biochemistry is unusual.
Their toxins evolved in isolation. That eccentricity is exactly what drug hunters want — molecules that do things warm-water creatures cannot. Baker’s lab has been working on Antarctic natural products for years.
This ascidian compound is one of several candidates. The melanoma result is the one that made news because it worked in mice without killing them.
That is a low bar in drug development. But it is the first bar, and they cleared it. The next step is scale.
The National Science Foundation paid for the collection. Someone will have to pay for the chemistry. Baker did not name a partner or a timeline.
He said the compound has the physiological properties to act like a drug. That is a scientist’s way of saying the molecule passes the first sniff test.
Sniff tests are not cures. They are the reason to keep working. The sea squirt that cost six weeks of Antarctic diving to collect has earned a second look.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Antarctic sea squirt toxin kills melanoma in mouse study”, “description”: “Six weeks of diving in water cold enough to kill. Depths of 130 feet. Half-hour bottom times. That was the price of collecting one tiny…”, “datePublished”: “2026-06-29T14:38:00+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Ava Anderson”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.2bme.xyz/”}}
